Latest Kalaris Therapeutics News & Updates

See the latest news and media coverage for Kalaris. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kalaris Therapeutics (Kalaris)

Clinical-stage biopharmaceutical company developing retinal disease treatments

kalaristx.com

Company type: Private company
Number of employees: 10–21
Industry: Pharmaceuticals

Last updated August 12

Latest news about Kalaris Therapeutics (Kalaris)

In short: Kalaris advanced TH103, completed the AlloVir merger, and reported positive Phase 1a data and financials.

Company announcements

August 11 Kalaris

Kalaris reports Q2 2026 financial results and business updates

Cash of $93.5 million funds operations into Q4 2027; Phase 1b/2 dosing ongoing with data expected in 1H 2027; Phase 3 on track for 2027.

July 13 Kalaris

Kalaris reports positive TH103 Phase 1a SAD results from expanded AMD cohorts

Expanded data reinforced vision and retinal improvements, with extended treatment durability and no inflammation at the 2.5mg dose.

June 12 Kalaris

Kalaris Therapeutics announces positive Phase 1a data for TH103

Results from the study will be presented at CTS Retina, showing safety and efficacy in wet AMD.

May 12 Kalaris

Kalaris reports Q1 2026 financial results and business updates

Net loss was $10.9 million, with $104.9 million cash; Phase 1b/2 study underway.

Media coverage

August 12 The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)

Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.

August 11 Vision Monday

VM - Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program

BERKELEY HEIGHTS, N.J.—Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a clinical stage biopharmaceutical company, has announced financial results for the second quarter ended June 30, 2026, and...

August 4 Caledonian Record

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. ...

Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (Nasdaq: KLRS), formerly AlloVir, Inc. (Nasdaq...

July 29 StockHouse

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

(2024-11-08 | NDAQ:ALVR) AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina...

Never miss news about Kalaris

Track Kalaris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kalaris competitors & trending companies

Browse news for competitors to Kalaris and other trending companies.